How to Apply for the Speciality Medicines Limited IPO: Step-by-Step Investment Guide

    Summary:


    Speciality Medicines Limited is a pharmaceutical distribution company engaged in supplying speciality formulations for chronic and complex conditions. The IPO is scheduled to open on 20 March 2026 and close on 24 March 2026. It comprises 23,50,000 shares with an issue size aggregating up to ₹29 crore. The price band is set between ₹117 and ₹124 per share, with a lot size of 1000 shares, and the shares are proposed to be listed on the BSE SME platform.


    Speciality Medicines Limited operates in the pharmaceutical distribution segment, focusing on the marketing and supply of speciality formulations used in the treatment of chronic and complex conditions. The company provides products in various dosage forms, including tablets, injections, and inhalers, catering to different therapeutic requirements. Its operations are structured around contract manufacturing for international markets and the distribution of sourced pharmaceutical products within domestic regions. This approach places the company within the broader pharmaceutical supply chain, with exposure to both domestic and overseas markets. The business model includes collaboration with manufacturing partners and a distribution-focused structure, which may influence its positioning within the pharmaceutical market.

    The application process for the IPO can be completed through the ASBA facility available via net banking or through a UPI-enabled trading platform. Investors are required to log in, select the IPO section, enter bid details such as the price band and lot size, and confirm the application by authorising the payment mandate. The application amount remains blocked in the bank account until the allotment process is completed, in accordance with applicable guidelines.

    For more details, visit the Speciality Medicines Limited IPO page.

    Speciality Medicines Limited IPO Details and Objectives

    Details

    Information

    IPO Date

    Mar 20, 2026 to Mar 24, 2026

    Issue Size

    23,50,000 shares (agg. up to ₹29 Cr)

    Price Band

    ₹117 to ₹124 per share

    Lot Size

    1000 shares

    Listing At

    BSE SME

    Market Maker

    Aikyam Capital Private Limited

    Purpose of the IPO

    • Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat
    • Product Registration in International Markets and Product Development for sale in international markets
    • Funding for Marketing and Promotional Activities
    • To Meet Working Capital Requirements
    • General corporate purposes

    Timeline of Speciality Medicines Limited IPO

    Event

    Date

    IPO Open Date

    Fri, Mar 20, 2026

    IPO Close Date

    Tue, Mar 24, 2026

    Tentative Allotment

    Wed, Mar 25, 2026

    Initiation of Refunds

    Fri, Mar 27, 2026

    Credit of Shares to Demat

    Fri, Mar 27, 2026

    Tentative Listing Date

    Mon, Mar 30, 2026

    Cut-off time for UPI mandate confirmation

    5 PM on Tue, Mar 24, 2026

    Pricing & Lot Size of Speciality Medicines Limited IPO

    Price Band for the IPO

    • ₹117 to ₹124 per share

    Minimum Lot Size and Application Details

    Application

    Lots

    Shares

    Amount

    Individual investors (Retail) (Min)

    2

    2,000

    ₹2,48,000

    Individual investors (Retail) (Max)

    2

    2,000

    ₹2,48,000

    S-HNI (Min)

    3

    3,000

    ₹3,72,000

    S-HNI (Max)

    8

    8,000

    ₹9,92,000

    B-HNI (Min)

    9

    9,000

    ₹11,16,000

    Speciality Medicines Limited IPO Application Process

    The Speciality Medicines Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:

    Step 1: Login to Your Trading Platform

    Access your trading account using the broker's app or website.

    Step 2: Navigate to the IPO Section

    Go to the IPO section to view active IPO listings.

    Step 3: Select the Open IPO and Click Apply

    Locate Speciality Medicines Limited IPO in the list of available IPOs and click the ‘Apply’ button.

    Step 4: Enter the Quantity of Shares You Wish to Apply For

    Specify the number of shares (lot size: 1000 shares) within the price band of ₹117 to ₹124 per share.

    Step 5: Provide Your UPI ID

    Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.

    Step 6: Confirm the Application

    Review your application details and confirm the UPI mandate before 5 PM on the last application day.

    Step 7: Complete the Process and Wait for Allotment

    Submit the application and monitor the allotment status to check if shares have been allocated to you.

    Shares Offered in Speciality Medicines IPO

    The allocation of shares in the Speciality Medicines IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.

    Investor Category

    Shares Offered

    QIB Shares Offered

    Not more than 2% of the Net Issue

    Retail Shares Offered

    Not less than 49% of Net Issue

    NII Shares Offered

    Not less than 49% of Net Issue

    This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.

    Financial Health and Performance

    Key Financial Metrics

    • Total Assets: Grew from ₹22.68 crore in FY24 to ₹45.57 crore as of Oct 2025.
    • Total income: Recorded at ₹36.93 crore in Oct 2025, as compared to ₹27.66 crore in FY24.
    • Profit After Tax (PAT): Reported at ₹6.06 crore in Oct 2025, and ₹2.93 crore in FY24.
    • Net Worth: Recorded at ₹36.47 crore in Oct 2025 in comparison to ₹15.06 crore in FY24.
    • Reserves & Surplus: Stood at ₹30.04 crore in Oct 2025, as compared to ₹9.95 crore in FY24.
    • Total Borrowing: Stood at ₹4.81 crore in Oct 2025, as compared to ₹2.86 crore in FY24.
    • EBITDA: Stood at ₹6.51 crore in Oct 2025 in comparison to ₹5.26 crore in FY24.

    Recent Performance and Growth Prospects

    • The company’s asset base has expanded over the recent period, indicating an increase in scale of operations and resource deployment across its business segments.
    • Income levels have shown an upward movement, reflecting higher business activity and broader market reach across domestic and international operations.
    • Profitability has improved over the same period, suggesting changes in cost structures, operational efficiency, or product mix.
    • Net worth has increased, supported by internal accruals and retained earnings, which may influence the company’s financial position.
    • Growth in reserves and surplus indicates accumulation of earnings within the business, which may support future operational requirements.
    • Borrowings have also increased during the period, which may reflect funding requirements linked to business expansion and working capital needs.
    • EBITDA has shown an upward trend, indicating changes in operating performance before accounting for interest, tax, depreciation, and amortisation.
    • The overall financial trend reflects changes in scale, profitability, and capital structure, which may influence the company’s operational direction.

    Investment Risks and Opportunities

    Potential Risks of Investing in the IPO

    • The company’s operations depend on contract manufacturing partners and third-party sourcing, which may influence supply continuity, product availability, and quality control processes.
    • Expansion into international markets involves regulatory approvals and product registrations, which may affect timelines, compliance requirements, and market entry across different geographies.

    Opportunities and Growth Potential

    • The company’s focus on speciality pharmaceutical formulations places it within a segment associated with demand for therapies targeting chronic and complex conditions across domestic and international markets.
    • Planned utilisation of IPO proceeds towards research and development, product registration, and marketing activities may support expansion of the product portfolio and geographic presence.

    Key Performance Indicator (KPI)

    KPI

    Oct 31, 2025

    Mar 31, 2025

    ROE

    18.11%

    37.85%

    ROCE

    16.68%

    33.39%

    Debt/Equity

    0.13

    0.17

    RoNW

    16.61%

    28.30%

    PAT Margin

    16.49%

    14.77%

    EBITDA Margin

    17.73%

    15.60%

    Price to Book Value

    2.19

    2.62

    Speciality Medicines Limited IPO Registrar & Lead Managers

    Registrar

    Lead Manager(s)

    Skyline Financial Services Pvt.Ltd.

    Unistone Capital Pvt.Ltd.

    Company Address of Speciality Medicines Limited

    913, One World West, S. No. 396, FP 119,

    Village- Vejalpur, Ahmedabad City,

    Ahmedabad, Gujarat, India,

    Ahmedabad, Gujarat, 380051

    Phone: +91 22 4604 5344

    Email: investors.grievances@specialitymedicine.com

    Website: https://www.specialitymedicine.com/

    Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Speciality Medicines IPO allotment status.

    Disclaimer :

    Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Publish Date: 23 Mar 2026

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    1 M+ Users

    4.8 App Rating

    4 Languages

    ₹7,300 Cr+ MTF Book

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |